Core Viewpoint - Ying Tai Medical (01501) announced a placement agreement to issue 35.2 million shares at a price of HKD 26 per share, representing a discount of approximately 16.13% from the closing price of HKD 31.00 on January 14, 2026 [1] Fund Utilization - The net proceeds from the placement are estimated to be approximately HKD 884 million, with 56.54% allocated for investments and potential acquisitions in the medical device industry to expand the product portfolio [1] - Approximately 23.75% of the proceeds will be used to repay existing interest-bearing bank loans [1] - About 19.71% will be allocated for general corporate purposes, including employee costs and daily operational expenses [1]

Group 1 - The core announcement is that Ying Tai Medical (01501.HK) has entered into a placement agreement with joint placement agents to sell 35.2 million shares at a price of HKD 26.00 per share, representing a discount of approximately 16.13% compared to the closing price of HKD 31.00 per share on the Stock Exchange [1] - If all placement shares are fully subscribed and settled, the total gross proceeds from the placement are expected to be approximately HKD 915 million, with net proceeds estimated at around HKD 884 million after deducting commissions and other related costs [1] - The net issue price per placement share is calculated to be HKD 25.12 [1]

香 港 交易 及 結 算 所 有限 公 司 及 香港 聯 合 交 易 所有 限 公 司 對 本公 告 的 內 容概 不 負 責， 對 其 準 確 性或 完 整 性 亦不 發 表 任 何 聲明 ， 並 明 確 表示 ， 概 不 對因 本 公 告全 部 或 任 何 部分 內 容 而 產生 或 因 倚 賴 該等 內 容 而 引 致的 任 何 損 失承 擔任何責任。 本 公 告 或 其 任 何 副 本概 不 得 直 接或 間 接 於 美 國境 內 或 有 關 刊發 或 派 發 屬違 法 的 任 何 其 他 司 法 權 區 刊 發 或 派 發 。 本 公 告 僅 作 參 考 用 途 ， 並 不 構 成 收 購、購買或認購本公司任何證券之邀請或要約。 本 公 告並 不 構 成 或 組成 於 美 國 境內 或 有 關 發 售屬 違 法 的 任 何其 他 司 法 權區 出 售 或購 買 或 認 購 證券 的 任 何 要約 或 招 攬 的 一部 分 。 本 公 告所 述 本 公 司股 份並無亦不會根據1933年美國證券 法（ 經修 訂 （）「美國證券法」）登記，且 不 得 於 美國 境 內 提 呈 發售 或 出 售 ，惟 根 ...

Group 1 - China Orient Asset Management (International) Holding Limited increased its stake in Ying Tai Medical (01501) by 160,000 shares at a price of HKD 30.0109 per share, totaling approximately HKD 4.8017 million [1] - Following the increase, the total number of shares held by China Orient Asset Management is now 18,844,200, representing an ownership percentage of 18.08% [1]

Group 1 - China Orient Asset Management (International) Holding Limited increased its stake in Ying Tai Medical (01501) by 160,000 shares at a price of HKD 30.0109 per share, totaling approximately HKD 4.8017 million [1] - Following the increase, the total number of shares held by China Orient Asset Management is now 18.8442 million, representing an ownership percentage of 18.08% [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 公司名稱: 上海瑛泰醫療器械股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01501 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 104,213,392 | RMB | | 1 RMB | | 104,213,392 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 104,213,392 | RMB | | 1 RMB | | 104,213,392 | | 2. 股份分類 | 普通股 | 股份類別 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海瑛泰醫療器械股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01501 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 104,213,392 | RMB | | 1 RMB | | 104,213,392 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 104,213,392 | RMB | | 1 RMB | | 104,213,392 | | 2. 股 ...

Core Insights - The China Securities Regulatory Commission (CSRC) has released a report on the status of domestic companies' overseas securities issuance and listing applications as of November 21, 2025, indicating ongoing interest in Hong Kong IPOs and full circulation of shares [1][2] Group 1: Companies Seeking Hong Kong IPOs - Dermavon Holdings Limited (德镁医药) is in the process of indirect overseas listing, with its application currently under review for supplementary materials [1][2] - Guangzhou Haote Energy Conservation Technology Co., Ltd. and Zhejiang Shimai Pharmaceutical Co., Ltd. are both pursuing direct overseas listings on the Hong Kong Stock Exchange [1][2] - Shenzhen Mindray Bio-Medical Electronics Co., Ltd. and Chengdu Canopus Robotics Technology Co., Ltd. are also applying for direct overseas listings [1][2] - Beijing Defeng New Journey Technology Co., Ltd. is seeking a direct overseas listing on the Hong Kong Stock Exchange [1][2] Group 2: Companies with Full Circulation Applications - Companies such as Youbao Online Technology Co., Ltd. and Yaojie Ankang (Nanjing) Technology Co., Ltd. have submitted applications for full circulation of shares, which have been received by the CSRC [1][2] - Other companies including Bama Tea Co., Ltd. and Shanghai Yingtai Medical Devices Co., Ltd. are also in the process of obtaining full circulation status [1][2] - Lianlian Digital Technology Co., Ltd. and Xuan Bamboo Biotechnology Co., Ltd. are among those seeking full circulation of shares on the Hong Kong Stock Exchange [1][2]

Core Insights - The China Securities Regulatory Commission (CSRC) has released a report on the status of domestic companies' overseas securities issuance and listing applications as of November 21, 2025, indicating ongoing activity in the Hong Kong IPO market [1] Group 1: Companies Seeking IPOs - Dermavon Holdings Limited (德镁医药有限公司) is in the process of indirect overseas listing with materials submitted to the Hong Kong Stock Exchange [3] - Haote Energy Conservation Technology Co., Ltd. (豪特节能) and Zhejiang Shimai Pharmaceutical Co., Ltd. (时迈药业) are both pursuing direct overseas listings on the Hong Kong Stock Exchange [3] - Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (迈瑞生物) is also seeking a direct overseas listing, with multiple financial institutions involved in the underwriting process [3] - Chengdu Canopus Robotics Technology Co., Ltd. (卡诺普机器人) and Beijing Defeng New Journey Technology Co., Ltd. (德风科技) are similarly applying for direct listings on the Hong Kong Stock Exchange [3] Group 2: Companies with Full Circulation Applications - Companies such as Youbao Online Technology Co., Ltd. (友宝在线), Yaojie Ankang (药捷安康), and Bama Tea Co., Ltd. (八马茶业) have submitted applications for full circulation of their shares, indicating a shift towards increased liquidity in the market [3] - Other companies like Shanghai Yingtai Medical Devices Co., Ltd. (瑛泰医疗) and Lianlian Digital Technology Co., Ltd. (连连数字) are also part of this trend, with applications received by the CSRC [3]

Core Viewpoint - Ying Tai Medical (01501.HK) has submitted a filing to the China Securities Regulatory Commission (CSRC) for the implementation of full circulation of its H-shares, indicating a strategic move to enhance liquidity and market presence [1] Summary by Relevant Sections - **Company Actions** - The company has applied to convert a total of 71,786,608 shares of domestic shares held by certain shareholders into H-shares for listing on the Hong Kong Stock Exchange [1] - The conversion and listing will occur once all necessary approvals from regulatory bodies, including the CSRC and the Stock Exchange, are obtained [1] - **Regulatory Compliance** - The company is not required to hold a shareholders' meeting to approve the conversion and listing as per its articles of association [1]